Progressive Multiple Sclerosis: Characteristics and Management

Neurologic Clinics

Volumn 29, Issue 2, 2011, Pages 423-434

  Hawker, Kathleen ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

MRI; Primary and secondary progressive multiple sclerosis; Relapsing remitting multiple sclerosis; Treatments

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE SEVERITY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKOPENIA; MENSTRUAL IRREGULARITY; MULTIPLE SCLEROSIS; NAUSEA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; URINARY TRACT INFECTION;

DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 79952832422     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2011.01.002     Document Type: Review

References (70)

1. Hauser S., Oksenberg J. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006, 52:61-76.
2. Noseworthy J.H., Lucchinetti C., Rodriguez M., et al. Multiple sclerosis. N Engl J Med 2000, 343:938.
3. Miller D.H., Leary S.M. Primary-progressive multiple sclerosis. Lancet Neurol 2007, 6:903-912.
4. Ebers G.C. Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol 2005, 252(Suppl 3):iii15-iii20.
5. McDonnell G.V., Hawkins S.A. Primary progressive multiple sclerosis: a distinct syndrome?. Mult Scler 1996, 2:137-141.
6. Rudick R. Mechanisms of disability progression in primary progressive multiple sclerosis: are they different from secondary progressive multiple sclerosis?. Mult Scler 2003, 9:210-212.
7. Vukusic S., Confavreux C. Primary and secondary progressive multiple sclerosis. J Neurol Sci 2003, 206:153-155.
8. Thompson A.J., Kermode A.G., MacManus D.G., et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ 1990, 300:631-634.
9. Lycklama à Nijeholt G.J., Van Wlderveen M.A., Castelijins J.A., et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain 1998, 121:687-697.
10. Thompson A.J., Kermode A.G., Wicks D., et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991, 29:53-62.
11. Ingle G.T., Stevenson V.L., Miller D.H., et al. Two-year follow-up study of primary and transitional progressive multiple sclerosis. Mult Scler 2002, 8:108-114.
12. Kidd D., Thorpe J.W., Kendall B.E., et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996, 60:15-19.
13. Stevenson V.L., Miller D.H., Rovaris M., et al. Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology 1999, 52:839-845.
14. van Walderveen M.A., Lycklama A.N.G., Ader H.J., et al. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol 2001, 58:76-81.
15. Ingle G.T., Sastre-Garriga J., Miller D.H., et al. Is inflammation important in early PPMS? a longitudinal MRI study. J Neurol Neurosurg Psychiatry 2005, 76:1255-1258.
16. Bieniek M., Altmann D.R., Davies G.R., et al. Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2006, 77:1036-1039.
17. Zhao Y., Petkau A.J., Traboulsee A., et al. Does MRI lesion activity regress in secondary progressive multiple sclerosis?. Mult Scler 2010, 16:434-442.
18. Kidd D., Thorpe J.W., Thompson A.J., et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993, 43(12):2632-2637.
19. Filippi M., Rocca M.A. MR imaging of gray matter involvement in multiple sclerosis: implications for understanding disease pathophysiology and monitoring treatment efficacy. AJNR Am J Neuroradiol 2010, 31(7):1171-1177.
20. Chard D.T., Griffin C.M., Parker G.J., et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002, 125:327-337.
21. Luks T.L., Goodkin D.E., Nelson S.J., et al. A longitudinal study of ventricular volume in early relapsing-remitting multiple sclerosis. Mult Scler 2000, 6:332-337.
22. Rudick R.A., Fisher E., Lee J.C., et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999, 53:1698-1704.
23. Losseff N.A., Webb S.L., O'Riordan J.I., et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996, 119(Pt 3):701-708.
24. Rovaris M., Judica E., Gallo A., et al. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain 2006, 129:2628-2634.
25. Ingle G.T., Stevenson V.L., Miller D.H., et al. Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 2003, 126:2528-2536.
26. Filippi M., Rovaris M., Rocca M.A. Imaging primary progressive multiple sclerosis: the contribution of structural, metabolic, and functional MRI techniques. Mult Scler 2004, 10(Suppl 1):S36-S44.
27. Filippi M., Agosta F. Magnetization transfer MRI in multiple sclerosis. J Neuroimaging 2007, 17(Suppl 1):22S-26S.
28. Rovaris M., Judica E., Sastre-Garriga J., et al. Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Mult Scler 2008, 14:455-464.
29. Lisak R.P. Neurodegeneration in multiple sclerosis: defining the problem. Neurology 2007, 68(22 Suppl 3):S5-S12.
30. DeStephano N., Giorgio A., Battalglini M., et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010, 74:1868-1876.
31. Trapp B., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu Rev Neurosci 2008, 31:247-269.
32. Confavreux C., Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006, 129:606-616.
33. Kremenchutzky M., Rice G.P., Baskerville J., et al. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006, 129:584-594.
34. Confavreux C., Vukusic S., Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003, 126:770-782.
35. Scalfari A., Neuhaus A., Degenhardt A. The natural history of multiple sclerosis; a geographically based study 10: relapses and long-term disability. Brain 2010, 133(Pt 7):1914-1929.
36. European Study Group on Interferon-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998, 352:1491-1497.
37. Filippi M., Anderson V.M., Altmann D.R. Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2010, 81:204-208.
38. Hawker K.S., O'Connor P., Freedman M.S., et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009, 66:460-471.
39. Oksenberg J., Baranzini S.E., Sawcer S., et al. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008, 9:516-526.
40. Baranzini S.E., Wang J., Gibson R.A., et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009, 18:767-778.
41. Matejuk A., Hopke C., Vandenbark A., et al. Middle aged male mice have increased severity of experimental autoimmune encephalomyelitis and are unresponsive to testosterone therapy. J Immunol 2005, 174:2387-2395.
42. Chen J., Buchanan J.B., Sparkman N.L., et al. Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system. Brain Behav Immun 2008, 22:301-311.
43. Godbout J.P., Chen J., Abraham J., et al. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J 2005, 19:1329-1331.
44. Hasler P., Zouali M. Immune receptor signaling, aging, and autoimmunity. Cell Immunol 2005, 233:102-108.
45. Sawada M., Sawada H., Nagatsu T. Effects of aging on neuroprotective and neurotoxic properties of microglia in neurodegenerative diseases. Neurodegener Dis 2008, 5:254-256.
46. Khaleeli Z., Ciccarelli O., Manfredonia F., et al. Predicting progression in primary progressive multiple sclerosis. Ann Neurol 2008, 63:790-793.
47. Sastre-Garriga J., Ingle G.T., Rovaris M. Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. Neurology 2005, 65:633-635.
48. Ingle G.T., Sastre-Garriga J., Miller D.H., et al. Does inflammation have a role in early PPMS: a longitudinal MRI study. Mult Scler 2003, 9:S13.
49. Kappos L., Radue E.W., O'Connor P., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401.
50. Polman C., O'Connor P., Havrdova E., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
51. The North American Study Group on Interferon beta-1b in Secondary Progressive MS Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004, 63:1788-1795.
52. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group Randomized controlled trial of interferon beta-1a in secondary progressive MS. Neurology 2001, 56:1496-1504.
53. Cohen J., Cutter G., Fischer J.S., et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002, 59:679-687.
54. Leary S.M., Miller D.H., Stevenson V.L., et al. Interferon beta-1a in primary progressive MS. Neurology 2003, 60:44-51.
55. Montalban X., Sastre-Garriga J., Tintoré M., et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler 2009, 15:1195-1205.
56. Hartung H.P., Gonsette R., König N., et al. Mitoxantrone in progressive multiple sclerosis: a placebo controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360:2018-2025.
57. Martinelli M., Radaelli L., Straffi H., et al. Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci 2009, 30:1590-1874.
58. Kita M., Cohen J.A., Fox R.J., et al. A phase II trial of mitoxantrone in patients with progressive forms of multiple sclerosis. Neurology 2004, 62(Suppl 5):A99.
59. Wolinsky J.S., Narayana P.A., O'Connor P., et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007, 61:14-24.
60. Pöhlau D., Przuntek H., Sailer M., et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 2007, 13:1007-1017.
61. Beutler E., Sipe J.C., Romine J.S., et al. The treatment of chronic progressive multiple sclerosis with cladrabine. Proc Natl Acad Sci U S A 1996, 93:1716-1720.
62. Rice G., Filippi M., Comi G., et al. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000, 54:1145-1155.
63. Goodkin D.E., Rudick R.A., VanderBrug Medendorp S., et al. Low-dose (7.5 mg) oral methotrexate is effective in reducing the rate of progression of neurological impairment in patients with chronic progressive multiple sclerosis. Ann Neurol 1995, 37:30-40.
64. Zephir H., de Seze J., Duhamel A., et al. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 2004, 218:73-77.
65. Pirko I., Rodriguez M. Pulsed intravenous methylprednisolone therapy in progressive multiple sclerosis: need for a controlled trial. Arch Neurol 2004, 61:1148-1149.
66. Kalkers N., Barkhof F., Bergers E., et al. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 2002, 8:532-553.
67. Saccardi R., Kozak T., Bocelli-Tyndall C., et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune disease working party database. Mult Scler 2006, 12:814-823.
68. Bowen J.D., Maravilla K., Margolin S.B. Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis. Mult Scler 2003, 9:280-283.
69. Mowry E.M., Pesic M., Grimes B., et al. Clinical predictors of early second event in patients with clinically isolated syndrome. J Neurol 2009, 256:1061-1066.
70. Vukusic S., Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol 2007, 20:269-274.